SCHEMBL26919222

SCHEMBL26919222

Cn1cc(S(=O)(=O)N2CCC(Nc3ncc(C#N)c(CC4CCCC4)n3)CC2)cn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 18/20 0.53
▸ CCNE1 P24864 12/20 0.53
▸ CCND1 P24385 8/20 0.51
▸ CDK6 Q00534 8/20 0.51
▸ CDK1 P06493 7/20 0.51
▸ CCNB1 P14635 7/20 0.51
▸ CCNT1 O60563 6/20 0.51
▸ CDK4 P11802 6/20 0.51
▸ CDK9 P50750 6/20 0.51
▸ CCND3 P30281 5/20 0.51
▸ CDK7 P50613 5/20 0.51
▸ CCNH P51946 5/20 0.51
▸ MNAT1 P51948 5/20 0.51
▸ CCNA2 P20248 6/20 0.49
▸ CCNK O75909 2/20 0.49
▸ CDK12 Q9NYV4 2/20 0.49
▸ CCNB2 O95067 2/20 0.47
▸ CCNE2 O96020 2/20 0.47
▸ CDK5 Q00535 2/20 0.47
▸ CDK5R1 Q15078 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30496646 1.00 CDK2 (0.53) CDK2CCNE1CCND1CDK6CDK1
SCHEMBL26941920 0.85 CDK2 (0.56) CDK2CCNE1CCND1CDK6CDK1
SCHEMBL26942400 0.85 CDK2 (0.55) CDK2CCNE1CCND1CDK6CDK1
SCHEMBL26946581 0.84 CDK2 (0.53) CDK2CCNE1CCND1CDK6CDK1
SCHEMBL24477981 0.83 CDK2 (0.53) CDK2CCNE1CCND1CDK6CDK1
SCHEMBL29631714 0.83 CDK2 (0.53) CDK2CCNE1CCND1CDK6CDK1
SCHEMBL26942778 0.83 CDK2 (0.53) CDK2CCNE1CCND1CDK6CDK1
SCHEMBL29763101 0.82 CDK2 (0.53) CDK2CCNE1CCND1CDK6CDK1
SCHEMBL26918782 0.82 CDK2 (0.53) CDK2CCNE1CCND1CDK6CDK1
SCHEMBL26942777 0.82 CDK2 (0.53) CDK2CCNE1CCND1CDK6CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250009745-A1 CDK INHIBITOR SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) 2025-01-09 — — US disclosed
EP-4289835-A1 CDK INHIBITOR Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) 2023-12-13 — — EP disclosed
EP-4289835-A1 CDK INHIBITOR Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) 2023-12-13 — — EP disclosed
CN-116472270-A CDK inhibitors 上海齐鲁制药研究中心有限公司 2023-07-21 — — CN disclosed
WO-2022166793-A1 CDK INHIBITOR 上海齐鲁制药研究中心有限公司 2022-08-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250009745-A1 CDK INHIBITOR CDK9, CDKL1, CDK6 CDK2 11/4885CCNE1 32/4885CCND1 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback